Safety, Pharmacokinetics, and Pharmacodynamics of the Autotaxin Inhibitor GLPG1690 in Healthy Subjects: Phase 1 Randomized Trials

por van der Aar, Ellen, Desrivot, Julie, Dupont, Sonia, Heckmann, Bertrand, Fieuw, Ann, Stutvoet, Simone, Fagard, Liesbeth, Van de Wal, Karen, Helmer, Eric
Publicado 2019

Rationale, design and objectives of two phase III, randomised, placebo-controlled studies of GLPG1690, a novel autotaxin inhibitor, in idiopathic pulmonary fibrosis (ISABELA 1 and...

por Maher, Toby M, Kreuter, Michael, Lederer, David J, Brown, Kevin K, Wuyts, Wim, Verbruggen, Nadia, Stutvoet, Simone, Fieuw, Ann, Ford, Paul, Abi-Saab, Walid, Wijsenbeek, Marlies
Publicado 2019

Phase Ib/II, open-label, dose-escalation study of LGX818, an oral selective BRAF inhibitor, in combination with MEK162, an oral MEK1/2 inhibitor, in patients with BRAF V600-depende...

por Kefford, Richard, Sullivan, Ryan J, Miller, Wilson H, Elez, Elena M, Tan, Daniel, Kim, Kevin B, Long, Georgina V, Flaherty, Keith T, Tai, David, Stutvoet, Simone, Maacke, Heiko, Whiley, Matt, Parseval, Laure Moutouh-de, Tabernero, Josep
Publicado 2014